综合医疗系统中复杂性肺炎旁积液与脓胸的胸膜腔内酶治疗使用情况及结局
该回顾性队列纳入Kaiser Permanente Northern California 21家医院1,730例接受抗生素、胸腔置管引流及至少1剂胸膜腔内酶治疗的复杂性肺炎旁积液或脓胸成人。完整MIST2方案剂量定义为阿替普酶10 mg与多链丝霉素5 mg各6剂、每24小时各2剂、至少连续2天,仅99/1,751次就诊(5.7%)达到,机构层面变异大(组内相关系数0.57)。完整MIST2方案与治疗升级或出血复合终点风险降低相关(HR 0.61,95%CI 0.43-0.88,P=0.009),并与住院时间缩短15%(95%CI 5%-23%,P=0.003;平均13.4天 vs 11.4天)相关。作者认为鉴于保护性关联,医院应考虑实施完整MIST2方案给药。
要点
- 完整MIST2方案剂量定义为阿替普酶10 mg与多链丝霉素5 mg各6剂、每24小时各2剂、至少连续2天,1,751次就诊中仅99次(5.7%)达到。
- 完整MIST2方案与治疗升级(第二根同期胸管或手术)或出血(输血或血肿手术清除)复合终点风险降低相关(HR 0.61,95%CI 0.43-0.88,P=0.009)。
- 完整MIST2方案与住院时间缩短15%相关(95%CI 5%-23%,P=0.003;平均13.4天 vs 11.4天)。
- 机构层面完整MIST2方案给药变异大(组内相关系数0.57)。
- 作者认为鉴于保护性关联,医院应考虑实施完整MIST2方案给药。
适用人群与场景
- 纳入:在Kaiser Permanente Northern California 21家医院住院、诊断为复杂性肺炎旁积液或脓胸、接受抗生素、胸腔置管引流及至少1剂胸膜腔内酶治疗的成人。
诊断标准与关键阈值
- 完整MIST2方案剂量定义:接受阿替普酶10 mg与多链丝霉素5 mg各6剂,每24小时各给药2剂,至少连续2天。
处置流程与药物剂量
- 胸膜腔内酶治疗:阿替普酶10 mg与多链丝霉素5 mg,每24小时各2剂,至少连续2天,共各6剂(完整MIST2方案剂量定义)。
研究设计与关键结果
- 研究类型:回顾性队列;样本量:1,730例成人、1,751次就诊;21家医院;人群:复杂性肺炎旁积液或脓胸接受抗生素、胸腔置管引流及至少1剂胸膜腔内酶治疗者。
- 主要暴露:完整MIST2方案剂量(阿替普酶10 mg与多链丝霉素5 mg各6剂、每24小时各2剂、至少连续2天),1,751次就诊中99次(5.7%)达到。
- 机构层面完整MIST2方案给药变异大(组内相关系数0.57)。
- 主要终点:治疗升级(第二根同期胸管或手术)或出血(输血或血肿手术清除)复合终点,498次就诊(28.4%)发生治疗升级,137次就诊(7.8%)发生出血;完整MIST2方案与复合终点风险降低相关(HR 0.61,95%CI 0.43-0.88,P=0.009)。
- 次要终点:完整MIST2方案与住院时间缩短15%相关(95%CI 5%-23%,P=0.003;平均13.4天 vs 11.4天)。
- 暴露与未暴露患者间合并症或疾病严重程度差异极小。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为鉴于完整MIST2方案剂量与治疗升级或出血风险降低及住院时间缩短相关,医院应考虑实施完整MIST2方案给药。
- 完整MIST2方案给药在21家医院间变异大(组内相关系数0.57),仅5.7%就诊达到完整剂量,提示实际给药方案与MIST2试验方案存在差距。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Second Multicenter Intrapleural Sepsis Trial (MIST2) trial showed that twice-daily dosing of intrapleural enzyme therapy (IET) for 3 days improved outcomes in patients with pleural infection. Many hospitals are unable to administer IET on that schedule.
RESEARCH QUESTION: What is the variation in full MIST2 regimen dosing of IET across 21 hospitals in adults hospitalized with complicated parapneumonic effusion or empyema? What are the associations between full MIST2 dosing and outcomes?
STUDY DESIGN AND METHODS: This study included a retrospective cohort of 1,730 adults hospitalized at Kaiser Permanente Northern California with complicated parapneumonic effusion or empyema who received antibiotics, tube thoracostomy, and at least 1 dose of IET. The primary exposure full MIST2 dosing was defined as receiving 6 doses of alteplase 10 mg and dornase 5 mg, with 2 doses of each medication being given in each 24-hour period for at least 2 consecutive days.
RESULTS: Facility-attributable variation in IET dosing was assessed using mixed-effects modeling. The primary outcome of treatment escalation (second concurrent chest tube or surgery) or bleeding (transfusion of blood products or surgical evacuation of hematoma) was evaluated in a time-to-event analysis with death as the competing risk. The secondary outcome was hospital length of stay. Of 1,751 encounters, full MIST2 dosing occurred in 99 encounters (5.7%). High facility-level variation was found in full MIST2 dosing (intraclass correlation coefficient, 0.57). Minimal differences in comorbidity or severity of illness were found between exposed and unexposed patients. Treatment escalation occurred in 498 encounters (28.4%); bleeding occurred in 137 encounters (7.8%). Full MIST2 dosing showed a protective association against treatment escalation or bleeding (hazard ratio, 0.61; 95% CI, 0.43-0.88; P = .009). Full MIST2 dosing was associated with 15% reduction (95% CI, 5%-23% reduction; P = .003) in hospital length of stay (mean, 13.4 days vs 11.4 days).
INTERPRETATION: Full MIST2 dosing was infrequent with a high degree of facility-level variation. Given the protective association, hospitals should consider delivering full MIST2 dosing.
参考来源
- Solbes E, Thai KK, Kipnis P, et al. Use of and Outcomes Related to Intrapleural Enzyme Therapy for Complicated Parapneumonic Effusion and Empyema in an Integrated Health System. Chest. 2025. PMID: 41386458. doi:10.1016/j.chest.2025.11.042
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。